Role of Erlotinib 100 mg/d in the Treatment of 
Advanced Adenocarcinoma Lung Cancer Failed to Previous Chemotherapy

Background and objective Erlotinib is a epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). The standard dose is 150 mg/d. But some patients have to reduce the dose or stop treatment due to its side effects. The aim of this study is to evaluate the efficacy and safety of erlotinib...

Full description

Bibliographic Details

Published in:	Chinese Journal of Lung Cancer
Main Authors:	Chunlei SHI, Baohui HAN, Aiqin GU, Liwen XIONG, Jie SHEN
Format:	Article
Language:	Chinese
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2011-06-01
Subjects:	Lung neoplasms Erlotinib Target therapy EGFR-TKI
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2011.06.09